Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

PHASE2CompletedINTERVENTIONAL

Enrollment

217

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions

Allergic RhinitisConjunctivitis

Interventions

DRUG

REGN5713

Administered subcutaneously (SC)

DRUG

REGN5714

Administered SC

DRUG

REGN5715

Administered SC

OTHER

Placebo

Administered SC

Trial Locations (3)

Kingston General Health Research Institute, Kingston

Inflamax Research Limited DBA Cliantha Research, Mississauga

Clinique Specialisee en Allergie de la Capitale, Québec

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY